{
    "title": "AXA FRAMLINGTON BIOTECH: High risk - and rewards - in the genes for fund boss Linden Thomson",
    "url": "https://www.dailymail.co.uk/money/investing/article-2934315/AXA-FRAMLINGTON-BIOTECH-High-risk-rewards-genes-fund-boss-Linden-Thomson.html",
    "date": "2015-01-31",
    "keywords": [
        "fund",
        "thomson",
        "biotech",
        "sector",
        "science",
        "framlington",
        "multicap",
        "cent",
        "investment",
        "cap",
        "share",
        "linden",
        "microbiology",
        "way",
        "egg",
        "cost",
        "cancer",
        "research",
        "idea",
        "discovery",
        "demonstration",
        "innovation",
        "technology",
        "concentration",
        "field",
        "work",
        "biotechnology",
        "bit",
        "sense",
        "microbiologist",
        "insight",
        "doubt",
        "spot",
        "outlook",
        "year",
        "returnsthe",
        "decade",
        "ftse",
        "allshare",
        "index",
        "todayit",
        "reward",
        "highrisk",
        "investor",
        "overreliance",
        "multitude",
        "history",
        "number",
        "performance",
        "manager",
        "equity",
        "article",
        "failure",
        "development",
        "profile",
        "drug",
        "sentiment",
        "term",
        "demand",
        "portfolio",
        "challenge",
        "gene",
        "therapy",
        "cempra",
        "contender",
        "exchange",
        "treatment",
        "focus"
    ],
    "category": [
        "money",
        "investing"
    ]
}